![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tessenderlo Group | EU:TESB | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 0.41% | 24.40 | 24.15 | 24.90 | 24.40 | 24.20 | 24.30 | 13,030 | 16:40:00 |
Tessenderlo Group (NYSE Euronext: TESB) announced today that it has completed the sale of its pharmaceutical ingredients activities in Calaire (France) and Farchemia (Italy) to International Chemical Investors Group (ICIG), a private industrial holding company.
On October 9 2012, the group announced its intention to divest the pharmaceutical ingredients activities Calaire and Farchemia. Information and consultation procedures were completed early November. After clearance by the merger control authorities , the sale was completed on December 5 2012.
This divestment is in line with Tessenderlo Group's strengthened focus on specialty products and services in the areas of food, agriculture, water management and valorizing bio-residuals.
Calaire and Farchemia employ some 360 employees.
Tessenderlo Group is a worldwide specialty company, focused on food, agriculture, water management and on valorizing bio-residuals. The group employs about 7,500 people and is a leader in most of its markets, with a consolidated revenue of 2.1 billion EUR in 2011. Tessenderlo Chemie NV is listed on NYSE Eurolist by Euronext Brussels and is part of Next 150 and BEL Mid indices. Financial News wires: Bloomberg: TESB BB - Reuters: TesBt.BR - Datastream: B:Tes
International Chemical Investors Group (ICIG) is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. Since inception in 2004, ICIG has acquired 17 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed. ICIG companies currently employ more than 3,300 people and operate 17 manufacturing facilities in Europe and the United States with total sales of approximately €700 million. For more info about International Chemical Investors Group: http://www.ic-investors.com
Media Relations | Investor Relations |
Kathleen IWENS | Philip LUDWIG |
Tel: +32 (0) 478 664 555 | Tel: +32 2 639 16 58 |
This press release is available in Dutch, French and English on the corporate website www.tessenderlogroup.com - under 'News & Media'
1 Year Tessenderlo Chart |
1 Month Tessenderlo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions